Clinical Trials · NCT02803918
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 23
- Start date
- May 2017
- Locations
- 11 sites, 6 countries
- Primary endpoint
- Number of patients with adverse events (AEs)